Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy and Ponatinib Followed by Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

  • End date
    Feb 8, 2024
  • participants needed
  • sponsor
    M.D. Anderson Cancer Center
Updated on 28 October 2022
chronic myeloid leukemia
myeloid leukemia
lymphoid leukemia
philadelphia chromosome
granulocyte colony stimulating factor
serum bilirubin level
serum lipase


This phase II trial studies how well low-intensity chemotherapy and ponatinib work in treating patients with Philadelphia chromosome-positive and/or BCR-ABL positive acute lymphoblastic leukemia that may have come back or is not responding to treatment. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, dexamethasone, methotrexate, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with rituximab and blinatumomab, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Ponatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Granulocyte colony stimulating factor helps the bone marrow make recover after treatment. Giving low-intensity chemotherapy, ponatinib, and blinatumomab may work better in treating patients with acute lymphoblastic leukemia.



I. To evaluate the complete molecular response (CMR) rate of ponatinib and blinatumomab in combination with low-intensity chemotherapy in patients with newly diagnosed Philadelphia chromosome (Ph)-positive and/or BAR-ABL-positive acute lymphoblastic leukemia (ALL). (Cohort

  1. II. To evaluate the overall response (OR; complete response [CR] + complete response with hematologic improvement [CRi]) in patients with relapsed/refractory disease. (Cohort 2)


I. To evaluate other clinical efficacy endpoints (complete cytogenetic response, complete molecular response [CMR] [for relapsed/refractory population], event-free survival and overall survival) and safety of the combination regimen.


I. To characterize the role of ABL1 kinase domain mutations on treatment failure and relapse in patients with Ph+ ALL treated with hyper-CVD plus ponatinib and blinatumomab.

II. To determine the impact of recurrent genomic alterations and ribonucleic acid (RNA) expression at diagnosis on relapse free survival (RFS) in patients with Ph+ ALL treated with hyper-CVD plus ponatinib and blinatumomab.

III. To investigate the impact of next-generation sequencing-based minimal residual disease assessment on relapse-free survival in patients with Ph+ ALL.

IV. To determine the effect on immune cell subsets in patients with Ph+ ALL treated with blinatumomab plus ponatinib.


CYCLES 1 and 3: Patients receive ponatinib orally (PO) once daily (QD) on days 1-21 of cycle 1 and on days 1-28 of subsequent cycles, cyclophosphamide intravenously (IV) twice daily (BID) over 3 hours on days 1-3, rituximab IV over 4-6 hours on days 1 and 11, vincristine IV over 15 minutes on days 1 and 11, and pegfilgrastim or filgrastim subcutaneously (SC) daily on day 4. Patients also receive methotrexate intrathecally via spinal tap on day 2 and cytarabine intrathecally on day 7 in the absence of disease progression or unacceptable toxicity.

CYCLES 2 and 4: Patients receive ponatinib PO QD on days 1-28, methotrexate IV over 24 hours on day 1 and intrathecally on day 8, cytarabine IV BID over 2-3 hours on days 2 and 3 and intrathecally on day 5, pegfilgrastim or filgrastim SC daily on day 4, and rituximab IV over 4-6 hours on days 1 and 8 in the absence of disease progression or unacceptable toxicity.

CYCLES 5-8: Patients receive blinatumomab via central catheter continuously over weeks 1-4 every 6 weeks. Patients also receive methotrexate intrathecally on day 1 of cycle 5 and on day 8 of cycle 6 and cytarabine intrathecally on day 7 of cycle 5 and on day 1 of cycle 6 in the absence of disease progression or unacceptable toxicity.


CYCLES 1-3, 5-7, 9-11, and 13-15: After 4 cycles of blinatumomab, if disease has not gotten worse, patients receive vincristine IV over 15 minutes on day 1, prednisone PO on days 1-5, and ponatinib PO QD on days 1-28.

CYCLES 4, 8, and 12: Patients receive blinatumomab via central catheter continuously over weeks 1-4 every 6 weeks and ponatinib PO QD on days 1-28.

Treatment repeats every 28 days for up to 15 cycles in the absence of disease progression or unacceptable toxicity. Patients unable to receive blinatumomab, you may receive maintenance therapy with vincristine, prednisone, and ponatinib for a total of about 24 cycles at the discretion of doctor.

POST-MAINTENANCE THERAPY: Patients receive ponatinib PO QD on days 1-28. Cycles repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and then every 6 months thereafter.

Condition Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Treatment Rituximab, cyclophosphamide, methotrexate, filgrastim, cytarabine, vincristine, pegfilgrastim, Ponatinib, Blinatumomab
Clinical Study IdentifierNCT03147612
SponsorM.D. Anderson Cancer Center
Last Modified on28 October 2022


Yes No Not Sure

Inclusion Criteria

Patients >= 18 years of age with previously untreated Ph-positive ALL (either t(9;22) and/or BCR-ABL positive) (includes patients initiated on first cycle of hyper-CVAD before cytogenetics known. These patients could have received one or two cycles of chemotherapy with or without other TKIs and still eligible
Performance status =< 2 (Eastern Cooperative Oncology Group [ECOG] scale)
If they achieved CR, they are assessable only for event-free and overall survival, or
If they failed to achieve CR, they are assessable for CR, event-free, and overall survival
Alanine aminotransferase (ALT) =< 3 x ULN
Patients >= 18 years of age with relapsed/refractory Ph-positive ALL or lymphoid
accelerated or blast phase chronic myelogenous leukemia (CML)
Aspartate aminotransferase (AST) =< 3 x ULN
Serum lipase and amylase =< 1.5 x ULN
Total serum bilirubin =< 2 x upper limit of normal (ULN), unless due to Gilbert's
Creatinine =< 2.0 mg/dl
Adequate cardiac function as assessed clinically by history and physical examination
Signed informed consent
Female patients who: are postmenopausal for at least 1 year before the screening
visit, OR are surgically sterile, OR if they are of childbearing potential, agree to
practice 2 effective methods of contraception, at the same time, from the time of
signing the informed consent through 4 months after the last dose of study drug, or
agree to completely abstain from heterosexual intercourse
Male patients, even if surgically sterilized (i.e., status post-vasectomy), who: agree
to practice effective barrier contraception during the entire study treatment period
and through 4 months after the last dose of study drug, or agree to completely abstain
from heterosexual intercourse

Exclusion Criteria

Active serious infection not controlled by oral or intravenous antibiotics
History of alcohol abuse
Known active hepatitis B. Patients with chronic hepatitis B who are on appropriate
viral suppressive therapy may be allowed after discussion with the principal
investigator (PI)
History of acute pancreatitis within 1 year of study or history of chronic
Uncontrolled hypertriglyceridemia
Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or
squamous cell carcinoma) that in the investigator's opinion will shorten survival to
less than 1 year
Active grade III-V cardiac failure as defined by the New York Heart Association
Uncontrolled, or active cardiovascular disease, specifically including, but not
restricted to: myocardial infarction (MI), stroke, or revascularization within 3
months; unstable angina or transient ischemic attack; congestive heart failure prior
to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of
normal per local institutional standards prior to enrollment; diagnosed or suspected
congenital long QT syndrome; clinically significant atrial or ventricular arrhythmias
as determined by the treating physician; prolonged corrected QT (QTc) interval on
pre-entry electrocardiogram (> 470 msec) unless corrected after electrolyte
replacement. or approved by cardiologist; Significant venous or arterial
thromboembolism including deep venous thrombosis or pulmonary embolism. Patients with
a history of treated prior superficial or catheter associated phlebitis will not be
considered as significant embolism and after discussion with principal investigator
(PI) will not be excluded from eligibility. Uncontrolled hypertension (diastolic blood
pressure > 90 mmHg; systolic > 140mmHg). Patients with hypertension should be under
treatment on study entry to effect blood pressure control
Taking any medications or herbal supplements that are known to be strong inhibitors of
CYP3A4 within at least 14 days or 5 half-lives before the first dose of ponatinib in
patients with newly diagnosed only
History or presence of clinically relevant central nervous system (CNS) pathology such
as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain
injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome
or psychosis. Patients with active CNS leukemia will NOT be excluded
Current autoimmune disease or history of autoimmune disease with potential CNS
Treatment with any investigational antileukemic agents or chemotherapy agents in the
last 7 days before study entry, unless full recovery from side effects has occurred or
patient has rapidly progressive disease judged to be life-threatening by the
Pregnant and lactating women will not be eligible; women of childbearing potential
should have a negative pregnancy test prior to entering on the study and be willing to
practice methods of contraception. Women do not have childbearing potential if they
have had a hysterectomy or are postmenopausal without menses for 12 months. In
addition, men enrolled on this study should understand the risks to any sexual partner
of childbearing potential and should practice an effective method of birth control
History of significant bleeding disorder unrelated to cancer, including: diagnosed
congenital bleeding disorders (e.g., von Willebrand's disease); and diagnosed acquired
bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
Patients with documented significant pleural or pericardial effusions unless they are
thought to be secondary to their leukemia
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note